Aprea Therapeutics
Yahoo Finance • 5 days ago
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking ca... Full story
Yahoo Finance • last month
Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Oversubscribed $30 million private placement closed, with proceeds expected to support ongoing development of APR-1051Two partial responses observed with continued encouraging tolerability in the ongoing Phase 1 dose escalation ACESOT-1051... Full story
Yahoo Finance • 2 months ago
Oracle upgraded, Planet Fitness downgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Wells Fargo upgraded United Therapeutic... Full story
Yahoo Finance • 2 months ago
Here Are Thursday’s Top Wall Street Analyst Research Calls: Alcoa, Chiron Real Estate, Clear Secure, Fortinet, Fresh Pet, Kennametal, Oracle, PayPal, United Therapeutics, and More
Quick Read: Risk assets soared higher on Wednesday on reports of a potential peace deal with Iran. Stocks, bonds, and precious metals all saw strong buying, as the major indices once again touched record highs. Investors should be careful... Full story
Yahoo Finance • 2 months ago
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting
DOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies... Full story
Yahoo Finance • 3 months ago
Aprea Therapeutics GAAP EPS of -$0.32 beats by $0.07
* Aprea Therapeutics press release [https://seekingalpha.com/pr/20438259-aprea-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a] (APRE [https://seekingalpha.com/symbol/APRE]): Q4 GAAP EPS of -$0.32... Full story
Yahoo Finance • 6 months ago
Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026
DOYLESTOWN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that target weaknesses in cancer cells wh... Full story
Yahoo Finance • 7 months ago
Aprea Therapeutics GAAP EPS of -$0.47, revenue of $1.84M
* Aprea Therapeutics press release [https://seekingalpha.com/pr/20303880-aprea-therapeutics-reports-third-quarter-2025-financial-results-and-provides-a-clinical] (APRE [https://seekingalpha.com/symbol/APRE]): Q3 GAAP EPS of -$0.47. * R... Full story
Yahoo Finance • 8 months ago
Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051
3 out of 4 patients achieved stable disease (per RECIST v1.1) at the 100 mg APR-1051 dose level in heavily pretreated gastrointestinal and gynecologic malignanciesDisease stabilization observed in patients with tumors harboring mutations r... Full story
Yahoo Finance • 10 months ago
Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference
DOYLESTOWN, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnera... Full story
- PM
Mentioned:
Yahoo Finance • last year
Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center
Preclinical data demonstrate potent single-agent and combination effects inhead and neck squamous cell carcinoma (HNSCC) models, including synergy with anti–PD-1 therapy Initial Phase 1 clinical update shows early disease control in first... Full story
Yahoo Finance • last year
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial Three patients in the 550 mg twice daily cohor... Full story
Yahoo Finance • last year
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 Twice daily (BID) dosing regimen in ongoing ABOYA-119 trial expected to maximize clinical... Full story
Yahoo Finance • last year
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)
DOYLESTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulner... Full story
Yahoo Finance • 3 years ago
Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
DOYLESTOWN, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported... Full story
Yahoo Finance • 3 years ago
Aprea Therapeutics to Host a Key Opinion Leader (KOL) Event on its Synthetic Lethality (SL) and DNA Damage Response (DDR) Pathways
DOYLESTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced... Full story
Yahoo Finance • 3 years ago
Aprea Unveils Initial Clinical Data on ATRi, ATRN-119, and Pre-Clinical Data on WEE1i, ATRN-1051, at AACR-NCI-EORTC International Conference Supporting Highly Differentiated Synthetic Lethality Portfolio
DOYLESTOWN, Pa., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced... Full story
Yahoo Finance • 3 years ago
Aprea Therapeutics Announces Two Posters at the Upcoming 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
DOYLESTOWN, Pa., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announce... Full story
Yahoo Finance • 3 years ago
Aprea Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
DOYLESTOWN, Pa., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea” or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced... Full story
Yahoo Finance • 3 years ago
Aprea Therapeutics Appoints Dr. Jean-Pierre Bizzari to its Board of Directors and Names Dr. Richard Peters as Chairman
DOYLESTOWN, Pa., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced... Full story